Search This Blog

Wednesday, September 9, 2026

JPMorgan downgrades Dyne Therapeutics to Underweight, cuts price target to $10

 

JPMorgan downgrades Dyne Therapeutics to Underweight, cuts price target to $10 from $17 on DM1 risk

  • JPMorgan cites increased risk to Dyne’s DM1 program after Novartis’ Phase 3 del-desiran trial failure.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)